Related references
Note: Only part of the references are listed.FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemia/reperfusion injury through activation of the AKT/GSK313/ β-catenin signaling pathway
Bingtian Xu et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP+-induced oxidative insult
Jiahong Zhong et al.
FREE RADICAL BIOLOGY AND MEDICINE (2019)
Intensified mitophagy in skeletal muscle with aging is downregulated by PGC-1alpha overexpression in vivo
Dongwook Yeo et al.
FREE RADICAL BIOLOGY AND MEDICINE (2019)
TRPM2 Promotes Neurotoxin MPP+/MPTP-Induced Cell Death
Yuyang Sun et al.
MOLECULAR NEUROBIOLOGY (2018)
Motor Complications in Parkinson's Disease: Striatal Molecular and Electrophysiological Mechanisms of Dyskinesias
Barbara Picconi et al.
MOVEMENT DISORDERS (2018)
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
Simon D. Harding et al.
NUCLEIC ACIDS RESEARCH (2018)
In vitro identification of mitochondrial oxidative stress production by time-resolved fluorescence imaging of glioma cells
Silvia Tomkova et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2018)
Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
Michael J. Curtis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Dual Effects of Human Placenta-Derived Neural Cells on Neuroprotection and the Inhibition of Neuroinflammation in a Rodent Model of Parkinson's Disease
Han Wool Kim et al.
CELL TRANSPLANTATION (2018)
Determinants of dopaminergic neuron loss in Parkinson's disease
Dalton James Surmeier
FEBS JOURNAL (2018)
Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP+-induced decline of mitochondrial membrane potential and oxidative stress
Jiahong Zhong et al.
REDOX BIOLOGY (2018)
VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function
Thomas Briston et al.
FRONTIERS IN ONCOLOGY (2018)
The role of mitochondria in axon development and regeneration
George M. Smith et al.
DEVELOPMENTAL NEUROBIOLOGY (2018)
5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease
Natalie E. Scholpa et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Up-regulation of autophagy-related gene 5 (ATG5) protects dopaminergic neurons in a zebrafish model of Parkinson's disease
Zhan-ying Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Loss of phosphodiesterase 4 in Parkinson disease Relevance to cognitive deficits
Flavia Niccolini et al.
NEUROLOGY (2017)
FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and antiinflammatory effects
Haibiao Guo et al.
NEUROPHARMACOLOGY (2017)
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease
Lena F. Burbulla et al.
SCIENCE (2017)
Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection
Hojin Kang et al.
ONCOTARGET (2017)
A simple ImageJ macro tool for analyzing mitochondrial network morphology in mammalian cell culture
Andrew J. Valente et al.
ACTA HISTOCHEMICA (2017)
Roflupram, a Phosphodiesterase 4 Inhibitior, Suppresses Inflammasome Activation through Autophagy in Microglial Cells
Tingting You et al.
ACS CHEMICAL NEUROSCIENCE (2017)
The isozyme selective phosphodiesterase-4 inhibitor, ABI-4, attenuates the effects of lipopolysaccharide in human cells and rodent models of peripheral and CNS inflammation
Joseph R. Hedde et al.
BRAIN BEHAVIOR AND IMMUNITY (2017)
Inhibition of Excessive Oxidative Protein Folding Is Protective in MPP+ Toxicity-Induced Parkinson's Disease Models
Sarka Lehtonen et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
Advances in dopamine receptor agonists for the treatment of Parkinson's disease
Fabrizio Stocchi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
The relationship between glucocerebrosidase mutations and Parkinson disease
Anna Migdalska-Richards et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Peroxisome proliferator-activated receptor-γ (PPARγ) agonist is neuroprotective and stimulates PGC-1α expression and CREB phosphorylation in human dopaminergic neurons
Johanna Makela et al.
NEUROPHARMACOLOGY (2016)
What is the function of mitochondrial networks? A theoretical assessment of hypotheses and proposal for future research
Hanne Hoitzing et al.
BIOESSAYS (2015)
Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolism
Liudmila Efremova et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP
John C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein
Carine Ciron et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2015)
Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP+
A. K. Krug et al.
CELL DEATH & DISEASE (2014)
PDE4 as a target for cognition enhancement
Wito Richter et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
PGC-1α, mitochondrial dysfunction, and Huntington's disease
Ashu Johri et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
Generation of Genetically-Modified Human Differentiated Cells for Toxicological Tests and the Study of Neurodegenerative Diseases
Stefan Schildknecht et al.
ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION (2013)
Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease
Giuseppa Mudo et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis
Pablo J. Fernandez-Marcos et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2011)
Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line
Diana Scholz et al.
JOURNAL OF NEUROCHEMISTRY (2011)
Profiling Changes in Gait Dynamics Resulting From Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Nigrostriatal Lesioning
Natalie R. S. Goldberg et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2011)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Nuclear entry of active caspase-3 is facilitated by its p3-recognition-based specific cleavage activity
Min Luo et al.
CELL RESEARCH (2010)
PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Carles Canto et al.
CURRENT OPINION IN LIPIDOLOGY (2009)
Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV
Lichuan Yang et al.
EXPERIMENTAL NEUROLOGY (2008)
Design, Synthesis, and Structure-Activity Relationship, Molecular Modeling, and NMR Studies of a Series of Phenyl Alkyl Ketones as Highly Potent and Selective Phosphodiesterase-4 Inhibitors
Shilong Zheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Parkinson's disease: clinical features and diagnosis
J. Jankovic
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators
Julie St-Pierre et al.
CELL (2006)
Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1α transcription and mitochondrial biogenesis in muscle cells
Zhidan Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein(s)
S Kamada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease
RM Kostrzewa et al.
AMINO ACIDS (2002)
CREB regulates hepatic gluconeogenesis through the coactivator PGC-1
S Herzig et al.
NATURE (2001)
Share Paper
